Profile

TheraVac Biologics is a late-stage preclinical company developing innovative immunotherapies for neurodegenerative and inflammatory diseases. Its proprietary active immunotherapy platform targets multiple disease mechanisms, with lead programs addressing two key drivers of neurodegeneration: tau aggregation and neuroinflammation. This approach positions TheraVac Biologics to create transformative therapies for a broad range of chronic and neurodegenerative diseases.

TheraVac Biologics logo

Website

theravacbio.com

Contact


Event details

Date: November 3 - 5, 2025

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences

Participants

22 in total